LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Strona główna・Stock List・MannKind Corp

MannKind Corp

Closed

SectorHealthcare

3.36 1.82

Buy Sell

Overview

Share price change

24h

Current

Min

3.3

Max

3.45

Key metrics
By Trading Economics
Income	-671K -17M
Sales	-22M 90M
P/E Sector Avg	140.5 49.701
EPS	-0.02
Profit margin	-18.431
Employees	591
EBITDA	5.9M 3.4M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+127.79% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	56M 924M
Previous open	1.54
Previous close	3.36

News Sentiment

By Acuity

60%

40%

292 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

4.079 / 4.323 Support & Resistance

MannKind Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 maj 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 maj 2026, 16:49 UTC

Earnings

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 maj 2026, 16:26 UTC

Major Market Movers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 maj 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 maj 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 maj 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 maj 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 maj 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 maj 2026, 21:53 UTC

Earnings

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 maj 2026, 21:02 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 maj 2026, 20:55 UTC

Earnings

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 maj 2026, 20:30 UTC

Hot Stocks

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 maj 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 maj 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 maj 2026, 20:20 UTC

Earnings

Webull 1Q Adj EPS 3c >BULL

21 maj 2026, 20:20 UTC

Earnings

Webull 1Q Rev $159.9M >BULL

21 maj 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 maj 2026, 20:18 UTC

Earnings

Webull 1Q Loss/Shr 4c

21 maj 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 maj 2026, 18:58 UTC

Earnings

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 maj 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 maj 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 maj 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 maj 2026, 17:01 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 maj 2026, 16:20 UTC

Market Talk

Earnings

Stellantis Targets Distant but Constructive -- Market Talk

21 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

127.79% upside

12 Months Forecast

Average 7.54 USD 127.79%

High 10 USD

Low 4.75 USD

Based on 8 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to MannKind Corp - Dist in the past 3 months.

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

292 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.